Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994705 · ClinicalTrials.gov registry record · Phase 1
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03994705: Clinical Trial Phase 1 study, sponsored by Cartesian Therapeutics.
NCT03994705 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03994705, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Primary Outcome
Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Descartes-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-06-11 |
| Phase | Phase 1 |
Why NCT03994705 stopped before completion
NCT03994705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03994705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03994705 about?
NCT03994705 is a clinical study titled "Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma". This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
What is the current status of trial NCT03994705?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-01. Estimated completion is 2021-06-11.
What interventions are being tested in trial NCT03994705?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Descartes-11 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03994705?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03994705's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI